Care Capital Properties Can’t Escape Securities Lawsuits
Last Updated on May 8, 2018
Klein v. Care Capital Properties, Inc. et al
Filed: July 10, 2017 ◆§ 1:17-cv-00920-UNA
Care Capital Properties faces more securities litigation in the wake of its proposed acquisition by Sabra Health Care REIT.
Care Capital Properties, Inc. Sabra Health Care REIT, Inc. PR Sub, LLC Sabra Health Care Limited Partnership
Delaware
Care Capital Properties, Inc. and a familiar lineup of co-defendants are facing another securities class action in the wake of a proposed acquisition by Sabra Health Care REIT, Inc., PR Sub, LLC, and Sabra Health Care Limited Partnership, who this time are also listed as defendants.
At issue in the lawsuit are allegations that the no solicitation clause, which prevents Care Capital from listening to alternative proposals, and $38.5 million termination fee included in the May 2017 merger agreement effectively lock up the transaction while precluding any other bidders from making competing offers to buy the company. Moreover, the complaint predictably claims the defendants submitted a false and incomplete registration statement to the US Securities and Exchange Commission that failed to include, among other items, defendant Sabra’s financial projects, analyses done by financial advisors complete with a fairness opinion, and the line items used in calculating unlevered free cash flows.
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
How Do I Join a Class Action Lawsuit?
Did you know there's usually nothing you need to do to join, sign up for, or add your name to new class action lawsuits when they're initially filed?
Read more here: How Do I Join a Class Action Lawsuit?
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.